Exploiting MEK Inhibitor-Mediated Activation of ERα for Therapeutic Intervention in ER-Positive Ovarian Carcinoma

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Hou, June Y ^a   Rodriguez Gabin, Alicia ^a   Samaweera, Leleesha ^a   Hazan, Rachel ^a   Goldberg, Gary L ^a   Horwitz, Susan Band ^a   McDaid, Hayley M ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; FULVESTRANT; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PF 0325901; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ESTROGEN RECEPTOR ALPHA GENE; FEMALE; GENE OVEREXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; RECEPTOR GENE; TRANSCRIPTION INITIATION; TREATMENT OUTCOME; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BENZAMIDES; CARCINOMA; CELL LINE, TUMOR; DIPHENYLAMINE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEEDBACK, PHYSIOLOGICAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MAP KINASE KINASE KINASES; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873502680     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054103     Document Type: Article

References (54)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, et al. (2011) SEER Cancer Statistics Review. National Cancer Institute Bethesda, MD, 1975-2008: Available: http://seer.cancer.gov/csr/1975_2008/. Based on November 2010 SEER data submission, posted to the SEER web site, 2011.
2. Ayhan A, Kurman RJ, Yemelyanova A, Vang R, Logani S, et al. (2009) Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis. The American journal of surgical pathology 33: 1220-1224.
3. Gross AL, Kurman RJ, Vang R, Shih Ie M, Visvanathan K, (2010) Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics. Journal of oncology 2010: 126295.
4. Hsu CY, Bristow R, Cha MS, Wang BG, Ho CL, et al. (2004) Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clinical cancer research: an official journal of the American Association for Cancer Research 10: 6432-6436.
5. Ho CL, Kurman RJ, Dehari R, Wang TL, Shih Ie M, (2004) Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer research 64: 6915-6918.
6. Vereczkey I, Serester O, Dobos J, Gallai M, Szakacs O, et al. (2011) Molecular characterization of 103 ovarian serous and mucinous tumors. Pathology oncology research: POR 17: 551-559.
7. Shelling AN, Cooke IE, Ganesan TS, (1995) The genetic analysis of ovarian cancer. British journal of cancer 72: 521-527.
8. Lannigan DA, (2003) Estrogen receptor phosphorylation. Steroids 68: 1-9.
9. Cunat S, Hoffmann P, Pujol P, (2004) Estrogens and epithelial ovarian cancer. Gynecologic oncology 94: 25-32.
10. Lau KM, Mok SC, Ho SM, (1999) Expression of human estrogen receptor-alpha and-beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proceedings of the National Academy of Sciences of the United States of America 96: 5722-5727.
11. Atsriku C, Britton DJ, Held JM, Schilling B, Scott GK, et al. (2009) Systematic mapping of posttranslational modifications in human estrogen receptor-alpha with emphasis on novel phosphorylation sites. Molecular & cellular proteomics: MCP 8: 467-480.
12. Clark DE, Poteet-Smith CE, Smith JA, Lannigan DA, (2001) Rsk2 allosterically activates estrogen receptor alpha by docking to the hormone-binding domain. The EMBO journal 20: 3484-3494.
13. Joel PB, Traish AM, Lannigan DA, (1998) Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. The Journal of biological chemistry 273: 13317-13323.
14. Langdon SP, Ritchie A, Young K, Crew AJ, Sweeting V, et al. (1993) Contrasting effects of 17 beta-estradiol on the growth of human ovarian carcinoma cells in vitro and in vivo. International journal of cancer 55: 459-464.
15. Rao BR, Slotman BJ, (1991) Endocrine factors in common epithelial ovarian cancer. Endocrine reviews 12: 14-26.
16. Argenta PA, Thomas SG, Judson PL, Downs LS Jr, Geller MA, et al. (2009) A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecologic oncology 113: 205-209.
17. Bowman A, Gabra H, Langdon SP, Lessells A, Stewart M, et al. (2002) CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clinical cancer research: an official journal of the American Association for Cancer Research 8: 2233-2239.
18. Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W, et al. (1996) Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. Gynecologic oncology 62: 4-6.
19. Papadimitriou CA, Markaki S, Siapkaras J, Vlachos G, Efstathiou E, et al. (2004) Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 66: 112-117.
20. Smyth JF, Gourley C, Walker G, MacKean MJ, Stevenson A, et al. (2007) Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clinical cancer research: an official journal of the American Association for Cancer Research 13: 3617-3622.
21. Suga S, Kato K, Ohgami T, Yamayoshi A, Adachi S, et al. (2007) An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer. Gynecologic oncology 105: 341-350.
22. Legrier ME, Yang CP, Yan HG, Lopez-Barcons L, Keller SM, et al. (2007) Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer research 67: 11300-11308.
23. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 358-362.
24. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, et al. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112.
25. Bliss CI, (1939) The toxicity of poisons applied jointly. Ann Appl Biol 26: 31.
26. Huang GS, Lopez-Barcons L, Freeze BS, Smith AB 3rd, Goldberg GL, et al (2006) Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice. Clinical cancer research: an official journal of the American Association for Cancer Research 12: 298-304.
27. Legrier M-E, Yang H-G, Horwitz SB, Mcdaid H (2007) Constitutively active AKT is associated with resistance to MEK-directed therapy. Proceedings of the 98th Annual Meeting of the American Association for Cancer Research: Abstract#2363.
28. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, et al. (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494.
29. de Leeuw R, Neefjes J, Michalides R, (2011) A role for estrogen receptor phosphorylation in the resistance to tamoxifen. Int J Breast Cancer 2011: 232435.
30. Yamnik RL, Holz MK, (2010) mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation. FEBS letters 584: 124-128.
31. Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF, et al. (2007) Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. Gynecologic oncology 106: 461-468.
32. O'Donnell AJ, Macleod KG, Burns DJ, Smyth JF, Langdon SP, (2005) Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocrine-related cancer 12: 851-866.
33. Ribieras S, Tomasetto C, Rio MC, (1998) The pS2/TFF1 trefoil factor, from basic research to clinical applications. Biochimica et biophysica acta 1378: F61-77.
34. Madsen J, Nielsen O, Tornoe I, Thim L, Holmskov U, (2007) Tissue localization of human trefoil factors 1, 2, and 3. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society 55: 505-513.
35. Regalo G, Wright NA, Machado JC, (2005) Trefoil factors: from ulceration to neoplasia. Cellular and molecular life sciences: CMLS 62: 2910-2915.
36. Karam SM, Tomasetto C, Rio MC, (2008) Amplification and invasiveness of epithelial progenitors during gastric carcinogenesis in trefoil factor 1 knockout mice. Cell proliferation 41: 923-935.
37. Buache E, Etique N, Alpy F, Stoll I, Muckensturm M, et al. (2011) Deficiency in trefoil factor 1 (TFF1) increases tumorigenicity of human breast cancer cells and mammary tumor development in TFF1-knockout mice. Oncogene 30: 3261-3273.
38. Yoon J, Deisboeck TS, (2009) Investigating differential dynamics of the MAPK signaling cascade using a multi-parametric global sensitivity analysis. PloS one 4: e4560.
39. Yoon YK, Kim HP, Han SW, Hur HS, Oh do Y, et al. (2009) Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol Cancer Ther 8: 2526-2536.
40. Yan L (2009) MK-2206: A potent oral allosteric AKT inhibitor. 100th AACR Annual Meeting: Oral Presentation- Invited Abstract #DDT01-1: Merck & Co., Inc.
41. Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, et al. (2007) RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 282: 14056-14064.
42. Bindels EM, Lallemand F, Balkenende A, Verwoerd D, Michalides R, (2002) Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells. Oncogene 21: 8158-8165.
43. Song RX, Chen Y, Zhang Z, Bao Y, Yue W, et al. (2010) Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. The Journal of steroid biochemistry and molecular biology 118: 219-230.
44. Fan P, Wang J, Santen RJ, Yue W, (2007) Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer research 67: 1352-1360.
45. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467: 596-599.
46. Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, et al (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. Journal of the National Cancer Institute 95: 484-486.
47. Arias-Pulido H, Smith HO, Joste NE, Bocklage T, Qualls CR, et al. (2009) Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecologic oncology 114: 480-485.
48. Seidman JD, Horkayne-Szakaly I, Cosin JA, Ryu HS, Haiba M, et al. (2006) Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum. Gynecologic oncology 103: 703-708.
49. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, et al. (2008) Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecologic oncology 108: 510-514.
50. Covens AL, Filiaci V, Gersell D, Lutman CV, Bonebrake A, et al. (2011) Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study. Gynecologic oncology 120: 185-188.
51. Petrangeli E, Lubrano C, Ortolani F, Ravenna L, Vacca A, et al. (1994) Estrogen receptors: new perspectives in breast cancer management. The Journal of steroid biochemistry and molecular biology 49: 327-331.
52. Bayliss J, Hilger A, Vishnu P, Diehl K, El-Ashry D, (2007) Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clinical cancer research: an official journal of the American Association for Cancer Research 13: 7029-7036.
53. de Leeuw R, Flach K, Bentin Toaldo C, Alexi X, Canisius S, et al. (2012) PKA phosphorylation redirects ERalpha to promoters of a unique gene set to induce tamoxifen resistance. Oncogene.
54. Houtman R, de Leeuw R, Rondaij M, Melchers D, Verwoerd D, et al. (2012) Serine-305 phosphorylation modulates estrogen receptor alpha binding to a coregulator peptide array, with potential application in predicting responses to tamoxifen. Mol Cancer Ther 11: 805-816.